On June 22, 2021, Codex DNA announced the closing of its initial public offering of 7,666,664 shares of common stock, including the full exercise of the underwriters’ option to purchase up to 999,999 additional shares of common stock, at a public offering price of $16.00 per share. The aggregate gross proceeds to Codex DNA from the offering were approximately $122.7 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Codex DNA. The company's common stock began trading on The Nasdaq Global Select Market on June 18, 2021, under the ticker symbol "DNAY."

A Wilson Sonsini Goodrich & Rosati team including Philip Oettinger, Marty Waters, Rob Kornegay, Jesse Schumaker, Bridget Balisy, and Sheri Martin represented Codex DNA in the transaction.

For more information, please see Codex DNA's press release.